Poolbeg Pharma (LON:POLB) Hits New 52-Week High – What’s Next?

Shares of Poolbeg Pharma PLC (LON:POLB) reached a new 52-week high during trading on Thursday . The stock traded as high as GBX 9.30 and last traded at GBX 9.30, with a volume of 2141301 shares traded. The stock had previously closed at GBX 8.95.

Analyst Upgrades and Downgrades

Separately, Shore Capital Group reaffirmed a “house stock” rating on shares of Poolbeg Pharma in a research note on Monday, July 13th.

Poolbeg Pharma Stock Up 3.9%

The stock has a market capitalization of £71.00 million, a P/E ratio of -9.89 and a beta of 1.83. The company has a fifty day moving average price of GBX 7.70 and a 200-day moving average price of GBX 6.19.

About Poolbeg Pharma

Poolbeg Pharma plc (AIM: POLB) is a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field. The Company’s lead asset, POLB 001, has the potential to expand administration of cancer immunotherapies from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of the life-threatening side effect, Cytokine Release Syndrome (CRS). As such, POLB 001 could increase the number of patients that can receive these life-saving treatments, thereby increasing the market opportunity.